ProShares Ultra Nasdaq Biotechnology (NASDAQ:BIB – Get Free Report) was the target of a large growth in short interest during the month of September. As of September 30th, there was short interest totaling 7,709 shares, a growth of 85.9% from the September 15th total of 4,147 shares. Based on an average daily volume of 5,937 shares, the days-to-cover ratio is currently 1.3 days. Approximately 0.9% of the shares of the company are sold short.
Institutional Trading of ProShares Ultra Nasdaq Biotechnology
A hedge fund recently bought a new stake in ProShares Ultra Nasdaq Biotechnology stock. Toth Financial Advisory Corp purchased a new stake in ProShares Ultra Nasdaq Biotechnology (NASDAQ:BIB – Free Report) during the third quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor purchased 1,022 shares of the exchange traded fund’s stock, valued at approximately $118,000. Toth Financial Advisory Corp owned about 0.12% of ProShares Ultra Nasdaq Biotechnology as of its most recent filing with the Securities and Exchange Commission.
ProShares Ultra Nasdaq Biotechnology Price Performance
BIB stock opened at $106.82 on Thursday. ProShares Ultra Nasdaq Biotechnology has a one year low of $65.01 and a one year high of $126.40. The stock has a market cap of $89.73 million, a price-to-earnings ratio of 20.68 and a beta of 1.20. The company has a fifty day moving average price of $113.40 and a two-hundred day moving average price of $97.44.
ProShares Ultra Nasdaq Biotechnology Company Profile
ProShares Ultra Nasdaq Biotechnology (the Fund) seeks daily investment results, before fees and expenses, that correspond to twice (200%) the daily performance of the Index. The return of the Fund for a period longer than a single trading day will be the result of each day’s returns compounded over the period, which will very likely differ from the inverse of the return of the Dow Jones United States Basic Materials Index (the Index) for that period. The Fund does not seek to achieve its stated investment objective over a period of time greater than one day.
Featured Articles
- Five stocks we like better than ProShares Ultra Nasdaq Biotechnology
- Tesla Wants to Make Its Own Chips—What Could Go Wrong?
- IREN Limited’s AI Pivot Gains Traction—But Can Its Data Centers Deliver?
- PBF Energy’s Stunning Rally Faces a Critical Test
- Citi Stock Falls Despite Earnings Beat: What Investors Need to Know
Receive News & Ratings for ProShares Ultra Nasdaq Biotechnology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ProShares Ultra Nasdaq Biotechnology and related companies with MarketBeat.com's FREE daily email newsletter.
